Precision Pathology Laboratory Services

12/16/2025

Physicians are talking about how CyPath® Lung enables them to intervene early and with confidence…

12/11/2025

Sharing another powerful insight from a physician using CyPath® Lung in daily practice. Noninvasive tools like CyPath® Lung support confident, informed decision-making by clinicians.

12/09/2025

A powerful reminder of why early, noninvasive testing matters.

We're proud to support clinicians with tools that reduce risk and help patients get answers sooner.

11/28/2025

We are grateful for the physicians, staff, and partners who share our mission of advancing early detection of lung cancer and improving patient outcomes. Thank you for your trust and collaboration.

11/26/2025

See what Dr. Nadarajah had to say about a "typical patient" for CyPath® Lung

11/25/2025

Congratulations to Dr. Jairo Rodriguez who was honored by the City of Brownsville for his dedication to early detection and prevention of lung disease. Brownsville city commissioners have proclaimed November 2025 as “Dr. Jairo Rodriguez Appreciation Month.”

11/14/2025

Where early lung cancer detection meets family-centered care. If you’re at the TAFP Annual Session & Primary Care Summit in Addison, come see our team! BioAffinity Technologies

11/08/2025

Lung cancer is still the leading cause of cancer deaths globally. Yet fewer than 1 in 5 people eligible for low-dose CT (LDCT) screening actually get screened.
US guidelines recommend LDCT screening for smokers and former smokers at risk for developing lung cancer. Annual screening can reduce the lung cancer death rate by up to 20% by detecting tumors at early stages.
At BioAffinity Technologies, we’re advancing noninvasive diagnostics like CyPath® Lung, designed to help physicians detect lung cancer early, when treatment is most effective and lives can be saved.
On Day, we join clinicians and advocates nationwide to raise awareness about lung cancer screening and improve accessibility to lifesaving LDCT screening.

10/17/2025

AI is changing how we diagnose cancer - delivering earlier and less invasive detection that can lead to treatment and longer, healthier lives. The U.S. Patent Office issued its intention to award bioAffinity Technologies a patent for our AI-built algorithm and flow cytometry platform to detect lung cancer. Harnessing AI with our novel flow cytometry platform has resulted in a test that produces high-precision, standardized, data-driven results to guide physicians on next steps in care for patients at high risk for lung cancer.

The US Patent and Trademark Office will issue BIAF a new patent on its flow cytometry+AI platform that detects lung cancer as early as Stage 1A.

09/26/2025

On World Lung Day, we celebrate the strength of patients and families facing lung disease and the hope that comes with progress in care.
At CyPath® Lung, our mission is to help detect lung cancer earlier, giving patients more time, more choices, and more moments with the people they love.
Together, let’s raise awareness and look forward to a future where healthier lungs mean longer, fuller lives.

09/23/2025

Deciding what to do with indeterminate lung nodules is a challenge.
CyPath® Lung makes it easier.
✅Noninvasive sputum collection
✅Flow cytometry analysis
✅92% sensitivity | 87% specificity
For patients: fewer unnecessary procedures.
For physicians: clearer, faster answers.
Explore how CyPath® Lung supports smarter screening in the carousel.

09/19/2025

Early detection saves lives.
CyPath® Lung offers a noninvasive and accurate test to help identify lung cancer in its earliest stages — when treatment is most effective.
By leveraging advanced flow cytometry and proprietary biomarkers, CyPath® Lung empowers physicians with better tools to support patient care.
Learn more about how this innovation is changing the way we approach lung cancer detection.
www.cypathlung.com